{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:36:10Z","timestamp":1769276170973,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T00:00:00Z","timestamp":1601164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T00:00:00Z","timestamp":1601164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Health Development Fund","award":["201614035"],"award-info":[{"award-number":["201614035"]}]},{"name":"CAMS Major Innovation Project","award":["2016-I2M -1-011"],"award-info":[{"award-number":["2016-I2M -1-011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Recent guidelines highlighted the association between atherosclerosis and triglyceride-enriched lipoproteins in patients with impaired glucose metabolism. However, evidence from prospective studies for long-term prognostic utility of low-density lipoprotein triglyceride (LDL-TG) in real-world patients with prediabetes (Pre-DM) or diabetes mellitus (DM) and coronary artery disease (CAD) is currently not available. The aim of the present study was to evaluate the impact of LDL-TG on major adverse cardiovascular events (MACEs) in patients with stable CAD under different glucose metabolism status.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 4381 patients with CAD were consecutively enrolled and plasma LDL-TG level was measured by an automated homogeneous assay. They were categorized according to both status of glucose metabolism [DM, Pre-DM, normal glycaemia regulation (NGR)] and tertiles of LDL-TG. All subjects were followed up for the occurrence of MACEs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>During a median of 5.1 (interquartile range 3.9 to 5.9) years\u2019 follow-up, 507 (11.6%) MACEs occurred. Cubic spline models showed a significant association between LDL-TG and MACEs in DM and Pre-DM but not in NGR. When the combined effect of elevated LDL-TG and glucose disorders was considered for risk stratification, the medium tertile of LDL-TG plus DM, and the highest tertile of LDL-TG plus Pre-DM or plus DM subgroups were associated with significantly higher risk of MACEs after adjustment of confounders including triglyceride [hazard ratios (95% confidence intervals): 1.843 (1.149\u20132.955), 1.828 (1.165\u20132.867), 2.212 (1.396\u20133.507), all p\u2009&lt;\u20090.05]. Moreover, adding LDL-TG into the original model increased the C-statistic from 0.687 to 0.704 (\u2206C-statistic\u2009=\u20090.016, p\u2009=\u20090.028) and from 0.734 to 0.749 (\u2206C-statistic\u2009=\u20090.014, p\u2009=\u20090.002) in Pre-DM and DM, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this longitudinal cohort study on real-world practice, higher LDL-TG was associated with worse outcomes among Pre-DM and DM patients with stable CAD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12933-020-01125-1","type":"journal-article","created":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T12:02:43Z","timestamp":1601208163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes"],"prefix":"10.1186","volume":"19","author":[{"given":"Jing-Lu","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye-Xuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na-Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Jue","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-4364","authenticated-orcid":false,"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,27]]},"reference":[{"issue":"4","key":"1125_CR1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450\u20138.","journal-title":"Circulation"},{"issue":"7","key":"1125_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","volume":"14","author":"Z Reiner","year":"2017","unstructured":"Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14(7):401\u201311.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"1125_CR3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M Miller","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Investigators PI-T: impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1125_CR4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","volume":"2","author":"MB Elam","year":"2017","unstructured":"Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O\u2019Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2(4):370\u201380.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"1125_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"OT Investigators","year":"2012","unstructured":"Investigators OT, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S. n\u2009\u2212\u20093 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"1125_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, Investigators R-I. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"1125_CR7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacc.2018.04.050","volume":"72","author":"A Saeed","year":"2018","unstructured":"Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, Coresh J, Guild CS, Boerwinkle E, Ballantyne CM, Hoogeveen RC. Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease. J Am Coll Cardiol. 2018;72(2):156\u201369.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1125_CR8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1125_CR9","first-page":"1060","volume":"21","author":"XH Ding","year":"2017","unstructured":"Ding XH, Ye P, Wang XN, Cao RH, Yang X, Xiao WK, Zhang Y, Bai YY, Wu HM. The predictive value of baseline LDL-TG level on major adverse cardiovascular events in a followed up cohort population. Eur Rev Med Pharmacol Sci. 2017;21(5):1060\u20134.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"1125_CR10","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI116411","volume":"91","author":"BJ McKeone","year":"1993","unstructured":"McKeone BJ, Patsch JR, Pownall HJ. Plasma triglycerides determine low density lipoprotein composition, physical properties, and cell-specific binding in cultured cells. J Clin Invest. 1993;91(5):1926\u201333.","journal-title":"J Clin Invest"},{"issue":"2","key":"1125_CR11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacc.2018.03.541","volume":"72","author":"M Miller","year":"2018","unstructured":"Miller M. Low-density lipoprotein triglycerides: widening the atherogenic landscape in CVD risk assessment. J Am Coll Cardiol. 2018;72(2):170\u20132.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"1125_CR12","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000146898.06923.80","volume":"110","author":"W Marz","year":"2004","unstructured":"Marz W, Scharnagl H, Winkler K, Tiran A, Nauck M, Boehm BO, Winkelmann BR. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2004;110(19):3068\u201374.","journal-title":"Circulation"},{"issue":"2","key":"1125_CR13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, Sousa-Uva M, Valensi P, Wheeler DC. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"7","key":"1125_CR14","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2337\/dc19-0274","volume":"42","author":"JL Jin","year":"2019","unstructured":"Jin JL, Cao YX, Zhang HW, Sun D, Hua Q, Li YF, Guo YL, Wu NQ, Zhu CG, Gao Y, Dong QT, Liu HH, Dong Q, Li JJ. Lipoprotein(a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes. Diabetes Care. 2019;42(7):1312\u20138.","journal-title":"Diabetes Care"},{"issue":"6","key":"1125_CR15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/HYPERTENSIONAHA.118.11063","volume":"71","author":"HH Liu","year":"2018","unstructured":"Liu HH, Cao YX, Li S, Guo YL, Zhu CG, Wu NQ, Gao Y, Dong QT, Zhao X, Zhang Y, Sun D, Li JJ. Impacts of prediabetes mellitus alone or plus hypertension on the coronary severity and cardiovascular outcomes. Hypertension. 2018;71(6):1039\u201346.","journal-title":"Hypertension"},{"key":"1125_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271\u201381.","journal-title":"Diabetes Res Clin Pract"},{"key":"1125_CR17","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/dc19-2367","volume":"43","author":"C Coopmans","year":"2020","unstructured":"Coopmans C, Zhou TL, Henry RMA, Heijman J, Schaper NC, Koster A, Schram MT, Kallen C, Wesselius A, den Engelsman RJA, Crijns H, Stehouwer CDA. Both prediabetes and type 2 diabetes are associated with lower heart rate variability: The Maastricht Study. Diabetes Care. 2020;43:1126\u201333.","journal-title":"Diabetes Care."},{"issue":"4","key":"1125_CR18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/dc16-1958","volume":"40","author":"JS Lee","year":"2017","unstructured":"Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: The Strong Heart Study. Diabetes Care. 2017;40(4):529\u201337.","journal-title":"Diabetes Care"},{"issue":"1","key":"1125_CR19","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc19-S002","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(1):S13\u201328.","journal-title":"Diabetes Care."},{"issue":"5","key":"1125_CR20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1373\/jalm.2017.024554","volume":"2","author":"Y Ito","year":"2018","unstructured":"Ito Y, Ohta M, Ikezaki H, Hirao Y, Machida A, Schaefer EJ, Furusyo N. Development and population results of a fully automated homogeneous assay for LDL triglyceride. J Appl Lab Med. 2018;2(5):746\u201356.","journal-title":"J Appl Lab Med"},{"issue":"3","key":"1125_CR21","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","volume":"51","author":"GG Gensini","year":"1983","unstructured":"Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.","journal-title":"Am J Cardiol"},{"key":"1125_CR22","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2147\/DMSO.S188856","volume":"12","author":"E Shemesh","year":"2019","unstructured":"Shemesh E, Zafrir B. Hypertriglyceridemia-related pancreatitis in patients with type 2 diabetes: links and risks. Diabetes Metab Syndr Obes. 2019;12:2041\u201352.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"8","key":"1125_CR23","first-page":"559","volume":"32","author":"PK Song","year":"2019","unstructured":"Song PK, Man QQ, Li H, Pang SJ, Jia SS, Li YQ, He L, Zhao WH, Zhang J. Trends in lipids level and dyslipidemia among Chinese adults, 2002\u20132015. Biomed Environ Sci. 2019;32(8):559\u201370.","journal-title":"Biomed Environ Sci"},{"issue":"4","key":"1125_CR24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364\u201373.","journal-title":"JAMA"},{"issue":"16","key":"1125_CR25","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","volume":"140","author":"NA Marston","year":"2019","unstructured":"Marston NA, Giugliano RP, Im K, Silverman MG, O\u2019Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308\u201317.","journal-title":"Circulation"},{"key":"1125_CR26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.atherosclerosis.2018.12.024","volume":"282","author":"G Silbernagel","year":"2019","unstructured":"Silbernagel G, Scharnagl H, Kleber ME, Delgado G, Stojakovic T, Laaksonen R, Erdmann J, Rankinen T, Bouchard C, Landmesser U, Schunkert H, Marz W, Grammer TB. LDL triglycerides, hepatic lipase activity, and coronary artery disease: an epidemiologic and Mendelian randomization study. Atherosclerosis. 2019;282:37\u201344.","journal-title":"Atherosclerosis"},{"key":"1125_CR27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.atherosclerosis.2016.06.019","volume":"251","author":"JJ Albers","year":"2016","unstructured":"Albers JJ, Slee A, Fleg JL, O\u2019Brien KD, Marcovina SM. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Atherosclerosis. 2016;251:454\u20139.","journal-title":"Atherosclerosis"},{"issue":"17","key":"1125_CR28","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","volume":"62","author":"JR Guyton","year":"2013","unstructured":"Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O\u2019Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1580\u20134.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1125_CR29","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, Park JG, White JA, Bohula EA, Braunwald E. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571\u201382.","journal-title":"Circulation"},{"issue":"12","key":"1125_CR30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1125_CR31","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tu\u00f1\u00f3n J, White HD, Zeiher AM, Schwartz GG, Steg PG. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1125_CR32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-019-0851-z","volume":"18","author":"X Ye","year":"2019","unstructured":"Ye X, Kong W, Zafar MI, Chen LL. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019;18(1):48.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1125_CR33","doi-asserted-by":"crossref","first-page":"890","DOI":"10.5551\/jat.48330","volume":"26","author":"H Hsu","year":"2019","unstructured":"Hsu H, Hsu P, Cheng MH, Ito Y, Kanda E, Schaefer EJ, Ai M. Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan. J Atheroscler Thromb. 2019;26(10):890\u2013914.","journal-title":"J Atheroscler Thromb"},{"issue":"32","key":"1125_CR34","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Bor\u00e9n J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokg\u00f6zoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J."},{"issue":"4","key":"1125_CR35","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.dsx.2019.05.034","volume":"13","author":"JC Fruchart","year":"2019","unstructured":"Fruchart JC, Santos RD, Yamashita S, Libby P. Residual vascular risk in diabetes\u2014Will the SPPARM alpha concept hold the key? Diabetes Metab Syndr. 2019;13(4):2723\u20135.","journal-title":"Diabetes Metab Syndr"},{"issue":"8","key":"1125_CR36","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","volume":"138","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. 2018;138(8):770\u201381.","journal-title":"Circulation"},{"issue":"1","key":"1125_CR37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-020-0991-1","volume":"19","author":"HM Colhoun","year":"2020","unstructured":"Colhoun HM, Leiter LA, M\u00fcller-Wieland D, Cariou B, Ray KK, Tinahones FJ, Domenger C, Letierce A, Israel M, Samuel R, Del Prato S. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovasc Diabetol. 2020;19(1):14.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01125-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T23:08:30Z","timestamp":1632697710000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01125-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,27]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01125-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,27]]},"assertion":[{"value":"7 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Our study complied with the Declaration of Helsinki and was approved by the hospital\u2019s ethical review board (Fu Wai Hospital & National Center for Cardiovascular Diseases, Beijing, China). Informed written consents were obtained from all patients enrolled in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Raul D. Santos has received honoraria related to consulting, research and\/or speaker activities from: Ache, Amgen, Astra Zeneca, Esperion, Kowa, Novo-Nordisk, Merck, MSD, Pfizer, PTC and Sanofi\/Regeneron. All other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}